0000950170-24-010460.txt : 20240202 0000950170-24-010460.hdr.sgml : 20240202 20240202160109 ACCESSION NUMBER: 0000950170-24-010460 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240201 FILED AS OF DATE: 20240202 DATE AS OF CHANGE: 20240202 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: de los Pinos Elisabet CENTRAL INDEX KEY: 0001889633 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40971 FILM NUMBER: 24591218 MAIL ADDRESS: STREET 1: C/O AURA BIOSCIENCES, INC. STREET 2: 85 BOLTON STREET CITY: CAMBRIDGE STATE: MA ZIP: 02140 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aura Biosciences, Inc. CENTRAL INDEX KEY: 0001501796 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320271970 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 80 GUEST STREET CITY: BOSTON STATE: MA ZIP: 01235 BUSINESS PHONE: (617)500-8864 MAIL ADDRESS: STREET 1: 80 GUEST STREET CITY: BOSTON STATE: MA ZIP: 01235 4 1 ownership.xml 4 X0508 4 2024-02-01 0001501796 Aura Biosciences, Inc. AURA 0001889633 de los Pinos Elisabet C/O AURA BIOSCIENCES, INC. 80 GUEST STREET BOSTON MA 01235 true true false false See Remarks false Common Stock 2024-02-01 4 A false 162935 0.00 A 324373 D Common Stock 131412 I By EdIP Revocable Trust Stock Option (Right to Buy) 7.77 2024-02-01 4 A false 237065 0 A 2034-01-31 Common Stock 237065 237065 D These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on February 15, 2025, subject to the Reporting Person's continued service as of each such vesting date. The shares are held by the Elisabet de los Pinos Revocable Trust U/D/T dated April 8, 2016, of which the Reporting Person is a trustee. The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2025 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date. President and Chief Executive Officer /s/ Julie Feder, as Attorney-in-Fact 2024-02-02